RecruitingNCT07231939

Use of Flozins (Empagliflozin/Dapagliflozin) for Prevention of AKI

FLOzins for pREveNtion of Contrast-inducEd Acute Kidney Injury (FLORENCE) Study

Sponsor

Collegium Medicum w Bydgoszczy

Enrollment

4,000 participants

Start Date

Nov 1, 2025

Study Type

OBSERVATIONAL

Conditions

Acute Kidney Injury Coronary Artery Disease Percutaneous Coronary Intervention Contrast-Induced Acute Kidney Injury

Summary

All consecutive patients hospitalized from 01.01.2020 to 30.09.2025 who underwent coronary angiography or PCI will be eligible for inclusion. The final analysis will be limited to individuals in whom the volume of ICM administered during the index procedure was between 50 and 500 mL and for whom both pre- and post-procedure serum creatinine measurements were available. The primary objective of the study is the effect of short-term and long-term SGLT2i therapy on the occurrence of CI-AKI in patients undergoing diagnostic or therapeutic procedures with ICM.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Flozin for people with acute kidney injury, contrast-induced acute kidney injury, and other related conditions. The study is currently recruiting participants at 1 location.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGFlozin

Patients who underwent percutaneous coronary interventions while using empagliflozin or dapagliflozin

Locations(1)

Collegium Medicum w Bydgoszczy

Bydgoszcz, Poland

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07231939

Related Trials

Influence of Human Albumin Supplementation on Kidney Dysfunction After Liver Transplantation

NCT065359458 locations

Safety and Clinical Performance of the Freesolve Resorbable Magnesium Scaffold (RMS) System in Subjects With Coronary Artery Lesions

NCT072582901 location

Product Surveillance Registry

NCT01524276395 locations

Does Urinary TIMP2 and IGFBP7 Can Identify High Risk Patients of Progression From Mild and Moderate to Severe Acute Kidney Injury During Septic Shock?

NCT035474141 location

DEBSCAN-IVL. Drug Eluting Balloon or Drug Eluting Stent to Treat CAlcified Nodules After IntraVascular Lithotripsy.

NCT0665783313 locations